This guide is continuously monitored and updated by our AI compliance engine. It tracks legislative changes, board rulings, and regulatory updates for Louisiana in real time — so you always have the most current compliance intelligence.
The telehealth compliance information for Louisiana presented on this page is provided for general informational purposes only and should not be construed as legal advice. The telehealth regulatory landscape is evolving rapidly, with state legislatures, medical boards, and federal agencies frequently updating rules, guidance, and enforcement priorities. While TrueEval makes every effort to keep this information current and accurate, we cannot guarantee that all details reflect the very latest regulatory changes at the time of your visit.
We strongly recommend consulting with a qualified healthcare attorney or compliance professional before making business decisions based on this information. For the most current regulatory requirements, refer directly to your state medical board and relevant licensing authorities. Last reviewed: February 2026.
Louisiana presents a dynamic and often complex regulatory environment for healthcare companies, characterized by a generally conservative approach to healthcare innovation balanced with recent legislative efforts to expand telehealth access. The state's regulatory landscape is primarily shaped by the Louisiana State Board of Medical Examiners (LSBME), the Louisiana Board of Pharmacy, and the Louisiana State Board of Nursing, among others. While not as overtly restrictive as some states, Louisiana maintains a robust Corporate Practice of Medicine (CPOM) doctrine, which significantly influences permissible business structures, particularly for non-physician-owned entities. Recent legislative actions, particularly in the wake of the COVID-19 pandemic, have aimed to codify and expand telehealth flexibilities, though certain restrictions, especially concerning the establishment of the patient-provider relationship and controlled substance prescribing, remain. The state has shown a willingness to adapt, with several bills introduced in recent years addressing telehealth parity, interstate licensure, and scope of practice. For companies expanding into Louisiana, a thorough understanding of these foundational principles, coupled with an awareness of ongoing legislative and board activities, is paramount. The business climate for healthcare operations requires careful navigation of CPOM restrictions, professional licensing requirements, and specific telehealth protocols to ensure compliance and avoid enforcement actions. Key legislative acts like Act 235 of the 2020 Regular Session have been instrumental in defining telehealth, while subsequent bills continue to refine its application. Companies must be prepared for a regulatory environment that prioritizes patient safety and physician oversight, often necessitating sophisticated compliance strategies and legal counsel to structure operations appropriately.
Louisiana maintains a strong Corporate Practice of Medicine (CPOM) doctrine, which prohibits corporations or other non-professional entities from practicing medicine or employing physicians to provide medical services. The legal basis for Louisiana's CPOM doctrine is primarily derived from statutory provisions regulating the practice of medicine and professional corporations, as well as longstanding judicial interpretations. Specifically, Louisiana Revised Statutes (La. R.S.) Title 37, Chapter 11, 'Medical Practice Act,' defines who may practice medicine and prohibits unlicensed individuals or entities from doing so. La. R.S. 12:1086 et seq. governs professional medical corporations, explicitly stating that only licensed individuals may be shareholders, directors, and officers. This means that non-physicians generally cannot own or control entities that directly provide medical services. Consequently, the direct employment of physicians by lay entities is generally prohibited. This doctrine is strictly enforced by the Louisiana State Board of Medical Examiners (LSBME), which views such arrangements as potentially compromising a physician's independent medical judgment and placing financial interests over patient care.
For telehealth companies, medspas, dental practices, and wellness clinics, this has significant implications. Non-physician ownership of the clinical entity providing medical services is generally not permitted. This necessitates the use of a 'friendly physician' model or a Management Services Organization (MSO) structure. In an MSO model, a separate, non-professional entity (the MSO) provides administrative, non-clinical services (e.g., billing, marketing, IT, real estate, equipment) to a physician-owned professional medical corporation (PC). The PC, owned solely by licensed physicians, employs the healthcare providers and delivers the clinical services. The MSO then charges the PC a service fee, which must be fair market value and not tied to patient volume or revenue, to avoid illegal fee-splitting or kickback allegations. The MSO cannot control clinical decision-making, dictate treatment protocols, or interfere with the physician-patient relationship.
Non-physicians can own the MSO, but they cannot own or control the professional entity. For dental practices, similar restrictions apply under the Louisiana Dental Practice Act (La. R.S. 37:751 et seq.). Medspas offering medical services (e.g., injectables, laser treatments) must ensure that the medical component is owned and operated by a licensed physician or a physician-owned PC, even if the aesthetic services are provided by other licensed professionals (NPs, PAs, RNs) under appropriate supervision. Wellness clinics providing medical services (e.g., IV therapy, hormone therapy) face the same CPOM scrutiny. The LSBME is vigilant in scrutinizing arrangements that appear to circumvent these ownership and control prohibitions. Any structure must clearly delineate the separation between clinical and administrative functions, with clinical autonomy firmly residing with the licensed medical professionals.
Louisiana has made significant strides in codifying telehealth regulations, largely driven by Act 235 of the 2020 Regular Session, which comprehensively defined and regulated telehealth services. This act established that a valid patient-provider relationship can be established via telehealth, provided that the standard of care is met, and the practitioner is licensed in Louisiana. The law permits the establishment of a patient-provider relationship without a prior in-person examination, which is crucial for direct-to-consumer telehealth models. However, the practitioner must ensure that the technology used is appropriate for the service and that the patient's identity is verified.
Permitted Modalities: Louisiana law permits various telehealth modalities: live interactive audio-visual (video conferencing) is generally preferred and explicitly allowed. Live interactive audio-only (telephone calls) is permitted when appropriate for the service and when video is not available or feasible, particularly for behavioral health services. Asynchronous 'store-and-forward' technology is also allowed, provided it meets the standard of care. Email, text messaging, and fax are generally considered insufficient as standalone modalities for establishing a patient-provider relationship or delivering comprehensive care, though they can be used for ancillary communications.
Registration Requirements: Louisiana does not impose specific 'telehealth registration' requirements for providers beyond their standard professional licensure with the relevant state board (e.g., LSBME, Board of Nursing, Board of Pharmacy). However, out-of-state providers must obtain a full Louisiana license to practice telehealth with patients located in Louisiana, unless they qualify for specific interstate compacts (e.g., IMLC for physicians, NLC for nurses) which grant privileges to practice in compact states.
Informed Consent: Informed consent for telehealth services is explicitly required. La. R.S. 40:1223.4 requires practitioners to obtain informed consent from the patient (or their legal representative) prior to initiating telehealth services. This consent must include information about the services, the technology used, privacy and security measures, potential risks and benefits, and the patient's right to withdraw consent. Documentation of this consent is mandatory and must be maintained in the patient's medical record.
Geographic Restrictions: There are no specific geographic restrictions within Louisiana for telehealth services, meaning a licensed practitioner can provide telehealth to any patient located within the state. However, the practitioner must be physically located in a state where they are licensed to practice, and the patient must be located in Louisiana for Louisiana licensure requirements to apply. Interstate compacts facilitate practice across state lines, but otherwise, a Louisiana license is required for patients in Louisiana.
Prescribing controlled substances via telehealth in Louisiana is subject to strict regulations, largely aligning with federal DEA requirements and state-specific mandates. While the COVID-19 Public Health Emergency (PHE) waivers temporarily relaxed some restrictions, the baseline rules, particularly for Schedule II controlled substances, are robust. Post-PHE, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in-person medical evaluation prior to prescribing controlled substances via telehealth, unless an exception applies. The DEA has proposed new rules that would allow for an initial telehealth evaluation for Schedule III-V non-narcotic controlled substances and buprenorphine for opioid use disorder, with subsequent in-person visits required within a specified timeframe. However, the final rules are still pending as of early 2025.
Schedules Permitted: Generally, prescribers can prescribe Schedule III, IV, and V controlled substances via telehealth after establishing a legitimate patient-practitioner relationship, provided it's within the usual course of professional practice and the standard of care is met. Prescribing Schedule II controlled substances via telehealth without a prior in-person examination is highly restricted and typically only permitted under specific, limited circumstances (e.g., during a declared public health emergency or for specific conditions where an in-person exam is deemed impractical and a legitimate medical purpose exists, per DEA guidance).
DEA Requirements: All practitioners prescribing controlled substances, regardless of modality, must hold a valid DEA registration. The DEA's 'telemedicine exception' to the Ryan Haight Act allows for prescribing controlled substances without an in-person exam if the practitioner is acting in accordance with a legitimate medical purpose and within the usual course of professional practice, and meets other criteria, such as being registered in the state where the patient is located. The DEA has indicated it will finalize new rules for telehealth prescribing post-PHE, which will dictate the long-term landscape.
PDMP Checking: Louisiana Revised Statutes (La. R.S.) 40:978.1 mandates that prescribers check the Louisiana Prescription Monitoring Program (PMP) database prior to prescribing or dispensing any Schedule II, III, or IV controlled substance. This check is required at the initial prescription and at least every 90 days thereafter for ongoing prescriptions. Failure to comply can result in disciplinary action by the relevant licensing board. The PMP must be checked regardless of whether the prescription originated from an in-person or telehealth encounter.
Quantity/Refill Limitations: Louisiana law imposes specific quantity and refill limitations for certain controlled substances. For example, opioid prescriptions for acute pain are generally limited to a seven-day supply for initial prescriptions, with exceptions for chronic pain or specific medical conditions (La. R.S. 40:978.2). Refills for Schedule II substances are prohibited, while Schedule III-V substances are limited to five refills within six months of the date of issue. These limitations apply equally to telehealth prescriptions.
Special Rules:
The scope of practice for mid-level providers in Louisiana is defined by their respective licensing boards and state statutes, generally requiring some level of physician collaboration or supervision, particularly for prescriptive authority and complex medical procedures. Louisiana does not grant full practice authority to Nurse Practitioners (NPs).
Nurse Practitioners (NPs): In Louisiana, NPs operate under a 'collaborative practice agreement' with a physician. La. R.S. 37:913 and rules promulgated by the Louisiana State Board of Nursing (LSBN) govern NP practice. An NP must have a signed collaborative practice agreement with a physician licensed in Louisiana. This agreement outlines the scope of practice, the types of services the NP can provide, and the methods of collaboration and consultation. While the agreement grants significant autonomy within the NP's scope, the physician remains ultimately responsible for the patient's overall care. Prescriptive authority for NPs is granted upon meeting specific educational and certification requirements and is exercised under the collaborative practice agreement. NPs can prescribe controlled substances (Schedules II-V) if authorized by their collaborative practice agreement and registered with the DEA, subject to state and federal regulations, including the PDMP check requirement.
Physician Assistants (PAs): PAs in Louisiana practice under the 'supervision' of a licensed physician, as outlined in La. R.S. 37:1360.21 et seq. and rules from the LSBME. A PA must have a supervising physician who is readily available for consultation. The supervising physician is responsible for the PA's actions and must review a certain percentage of the PA's charts. The scope of practice for a PA is determined by the supervising physician and must be within the physician's own scope of practice and the PA's education and experience. PAs can prescribe controlled substances (Schedules II-V) if authorized by their supervising physician, registered with the DEA, and compliant with state and federal prescribing laws, including the PDMP. PAs cannot practice independently.
Medical Assistants (MAs) in Medspas: Medical assistants in Louisiana generally have a limited scope of practice, primarily involving administrative and delegated clinical tasks that do not require independent medical judgment. Their scope is typically defined by the delegating physician and generally includes tasks like taking vital signs, preparing patients for exams, and assisting with procedures. MAs cannot perform procedures that require a license, such as injections (e.g., Botox, fillers), laser treatments, or IV insertions. In medspas, these procedures must be performed by a licensed physician, NP, PA, or a registered nurse (RN) under appropriate supervision and delegation, depending on the specific procedure and the RN's scope of practice. Delegation must be in accordance with LSBME and LSBN rules, ensuring the delegating practitioner is physically present or immediately available as required by the complexity of the task and the MA's training.
Supervision Requirements: The level of supervision required varies by profession and task. For NPs, it's a collaborative agreement. For PAs, it's direct supervision by a physician. For RNs and MAs, delegation rules dictate the level of oversight, often requiring the delegating practitioner to be on-site or readily available. Strict adherence to these supervision and delegation rules is critical to avoid charges of unlicensed practice or improper delegation.
Navigating Louisiana's Corporate Practice of Medicine (CPOM) doctrine necessitates careful business structuring, with the Professional Corporation (PC) and Management Services Organization (MSO) model being the predominant compliant framework. This structure is essential for any entity providing medical services, including telehealth platforms, medspas, and specialty clinics.
PC-MSO Structures: This model is almost universally needed in Louisiana to comply with CPOM. A Professional Medical Corporation (PC) must be formed, owned exclusively by one or more licensed Louisiana physicians. This PC is the entity that directly employs or contracts with other licensed healthcare providers (NPs, PAs, RNs) and delivers all clinical services. The PC holds all necessary clinical licenses and permits (e.g., clinic licenses, DEA registrations). A separate, non-professional entity, the MSO, is formed to provide all non-clinical, administrative, and management services to the PC. The MSO can be owned by non-physicians or investors. Services provided by the MSO typically include billing, scheduling, marketing, IT support, facility management, equipment leasing, and human resources for administrative staff. The MSO charges the PC a fair market value (FMV) fee for these services.
Fee-Splitting Rules: Louisiana has strict prohibitions against fee-splitting, which generally means that a licensed healthcare professional cannot divide or share fees for professional services with an unlicensed individual or entity. La. R.S. 37:1285(A)(14) prohibits physicians from dividing fees for medical services with any person not licensed to practice medicine. In the PC-MSO model, the MSO's fee must be a fixed fee or a percentage of gross revenue that is not tied to the volume or value of referrals, and demonstrably at FMV for the services rendered. Any arrangement where the MSO's compensation is directly linked to the number of patients seen or the revenue generated from specific medical procedures could be construed as illegal fee-splitting or an unlawful inducement. The LSBME scrutinizes these arrangements to ensure the MSO does not exert undue influence over clinical decision-making or profit directly from the provision of medical services.
Management Services Agreement (MSA) Requirements: The relationship between the PC and the MSO is formalized through a comprehensive Management Services Agreement (MSA). This agreement must clearly delineate the responsibilities of each entity, explicitly stating that the PC retains sole control over all clinical decisions, hiring and firing of clinical staff, and patient care protocols. The MSA should detail the specific services provided by the MSO, the compensation structure (FMV), the term of the agreement, and provisions for termination. It is critical that the MSA does not grant the MSO any authority over the practice of medicine or the employment of licensed professionals providing clinical services. The MSA should also address compliance with HIPAA, Stark Law, and Anti-Kickback Statute principles, even if not directly applicable, to demonstrate a commitment to ethical practices.
Professional Corporation Requirements: As per La. R.S. 12:1086 et seq., a professional medical corporation must be incorporated under the Louisiana Professional Corporation Act. All shareholders, directors, and officers who perform professional services for the corporation must be licensed physicians in Louisiana. The corporate name must comply with LSBME rules, often including 'P.C.' or 'Professional Corporation.' These entities are subject to specific reporting requirements to the Secretary of State and the LSBME.
Structuring Ownership for Compliance: For telehealth companies, this means the technology platform and administrative functions can reside in the MSO, but the actual medical practice (the 'medical group' or 'provider network') must be a physician-owned PC. For medspas, the aesthetic services that are medical in nature (e.g., injectables, lasers) must be performed by a physician-owned PC. Non-medical services (e.g., facials, massages) can be offered by a separate, non-professional entity. Dental practices operate under similar professional corporation requirements under the Louisiana Dental Practice Act. Careful legal review of all agreements and corporate documents is essential to ensure strict adherence to Louisiana's CPOM and fee-splitting prohibitions.
Louisiana's regulatory landscape for healthcare has seen several key developments and ongoing legislative discussions, particularly concerning telehealth and interstate practice. These changes reflect a continued effort to balance access to care with patient safety and professional oversight.
Telehealth Legislation (2024-2025): While Act 235 of 2020 laid the groundwork for telehealth, subsequent legislative sessions have refined its application. Bills introduced in 2024 and expected to continue into 2025 have focused on ensuring payment parity for telehealth services, expanding the types of services eligible for reimbursement, and clarifying the role of various healthcare professionals in delivering virtual care. There is ongoing discussion regarding permanent rules for controlled substance prescribing via telehealth post-PHE, aligning with federal DEA proposals. The Louisiana Department of Health (LDH) and professional boards are actively monitoring federal guidance to adapt state regulations. Specific bills have addressed mental health parity for telehealth and expanding access to school-based telehealth services.
Interstate Licensure Compacts: Louisiana is an active participant in several interstate licensure compacts, which significantly impact the ability of out-of-state providers to practice in the state via telehealth:
Board Actions and Enforcement: The Louisiana State Board of Medical Examiners (LSBME) continues to be vigilant in enforcing the Corporate Practice of Medicine (CPOM) and improper delegation. Recent enforcement cases have focused on medspas operating without adequate physician supervision or ownership, and telehealth companies found to be prescribing controlled substances without proper patient evaluations or adherence to PMP requirements. The LSBME has also issued guidance and advisories regarding the appropriate use of telehealth for specific services, emphasizing the importance of maintaining the standard of care and proper documentation. There's an increased focus on ensuring that physician oversight in PC-MSO models is substantive and not merely a 'rubber stamp' arrangement.
GLP-1 and Weight Loss Services: With the rise of GLP-1 medications, the LSBME has informally communicated increased scrutiny on telehealth providers offering weight loss services. Emphasis is placed on comprehensive patient assessment, appropriate diagnostic criteria, and ongoing monitoring, cautioning against 'pill mill' type operations for weight-loss drugs. While not a formal regulation yet, this signals an area of heightened enforcement interest.
Entering the Louisiana healthcare market, whether as a brick-and-mortar practice or a telehealth brand, requires a methodical approach to ensure compliance with its unique regulatory environment. Here's actionable guidance:
Step-by-Step Compliance Checklist:
Common Pitfalls to Avoid:
Timeline Expectations:
Proactive engagement with Louisiana-specific legal counsel and compliance experts is invaluable to navigate these complexities successfully.
This article outlines the Centers for Medicare & Medicaid Services (CMS) requirements for healthcare providers offering telehealth services, focusing on credentialing and Medicare enrollment. It details the specific regulations and flexibilities that impact providers seeking to bill Medicare for virtual care, emphasizing the importance of compliance for continued participation.
State dental boards are actively defining the scope and standards for teledentistry, impacting how dental professionals can provide remote care. These regulations often address patient-provider relationships, technology requirements, consent, and record-keeping, emphasizing parity with in-person care standards. Compliance is crucial for dental practices expanding into virtual services to avoid regulatory scrutiny.
The provision of IV vitamin therapy and hydration services via telehealth requires strict adherence to state-specific regulations regarding the establishment of a valid practitioner-patient relationship, physical examination requirements, and supervision protocols. Many states mandate an in-person initial examination or specific telehealth modalities to ensure patient safety and appropriate medical oversight for these invasive procedures. Healthcare businesses offering these services must meticulously review and comply with the medical practice acts and board rules of each state where they operate.
Medspas leveraging telehealth for oversight across multiple states face complex and varying medical director requirements. Understanding the specific state laws governing physician supervision, corporate practice of medicine, and telehealth regulations is crucial for compliance and avoiding legal pitfalls.
The FDA has issued multiple warnings and guidance regarding the use of compounded semaglutide and tirzepatide, emphasizing that these compounded versions are not FDA-approved and may pose risks. This regulatory stance significantly impacts telehealth weight loss programs that rely on these medications, highlighting critical compliance considerations for prescribers and pharmacies.
Full physician-led clinical encounters with prescribing authority — real provider-patient relationships, not just clearance visits.
Board-certified medical directors for telehealth platforms, medspas, IV therapy clinics, dental sleep medicine, chiropractic practices, and more.
Structured agreements between physicians and mid-level providers ensuring compliant care delivery.
Navigate Corporate Practice of Medicine laws with state-specific compliance frameworks and legal structures.
Systematic clinical documentation reviews ensuring quality standards and regulatory compliance.
Receive instant notifications when Louisiana changes healthcare regulations.
Subscribe to AlertsGet a customized compliance framework for your healthcare operations in Louisiana — telehealth, medspa, IV therapy, or brick-and-mortar. Our team will guide you through every regulatory requirement.